EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Refractory Form of Chronic Idiopathic Demyelinating Polyneuropathy with Rituximab Effect: A Case Report

Edvard Ehler, Tomáš Jurka, Ivana Štětkářová

Acta Medica (Hradec Kralove, Czech Republic) · 2026 · 69 (2) · 75-80

DOI: 10.14712/18059694.2026.22 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Acta Medica (Hradec Kralove, Czech Republic), online erschienen am 11.08.2026. Verfasst von Edvard Ehler und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Health Studies, Pardubice University and Pardubice Regional Hospital, Pardubice, Czech Republic. edvard.ehler@nem…. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Rituximab, Immunologic Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The basic characteristic of chronic idiopathic demyelinating polyneuropathy (CIDP) is demyelination of peripheral nerves of autoimmune origin. Antibodies against various myelin sheath proteins play an important role in the pathogenesis of the disease. Cell-mediated immunity, characterised by T-cell and macrophage infiltration in peripheral nerves and spinal roots, is also significantly involved (1). Treatment of CIDP is aimed at suppressing inflammation, but also at removing autoantibodies, cytokines and other pro-inflammatory molecules from the blood. Treatment options include corticosteroids, (intravenous or subcutaneous) immunoglobulins, and plasma exchange (plasmapheresis). If a patient with CIDP does not show an adequate clinical response to these three treatment modalities, it is then refractory CIDP. Based on various studies, this affects up to 10% of patients. We present here a patient with CIDP whose condition gradually stopped improving after all three commonly used treatment modalities (corticosteroids, immunoglobulins, and plasmapheresis). His neurological findings were very severe. The case was ultimately diagnosed as a refractory form of CIDP, which is discussed here in the light of current knowledge of this issue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingRituximabImmunologic FactorsHumansMaleMiddle AgedPlasmapheresisPlasma Exchange

Stichwörter der Autor:innen

Chronic Inflammatory Demyelinating PolyradiculoneuropathyRituximabautoimmune diseasesimmunotherapyperipheral nervous system diseasesplasma exchange

Substanzen

RituximabImmunologic Factors

Autor:innen und Institutionen

  • Department of Neurology, Faculty of Health Studies, Pardubice University and Pardubice Regional Hospital, Pardubice, Czech Republic. edvard.ehler@nempk.cz.
  • Department of Neurology, Faculty of Health Studies, Pardubice University and Pardubice Regional Hospital, Pardubice, Czech Republic.
  • Department of Neurology, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic.

Zitieren

APA

Ehler, E., Jurka, T., & Štětkářová, I. (2026). Refractory Form of Chronic Idiopathic Demyelinating Polyneuropathy with Rituximab Effect: A Case Report. Acta Medica (Hradec Kralove, Czech Republic), 69(2), 75-80. https://doi.org/10.14712/18059694.2026.22

Vancouver

Ehler E, Jurka T, Štětkářová I. Refractory Form of Chronic Idiopathic Demyelinating Polyneuropathy with Rituximab Effect: A Case Report. Acta Medica (Hradec Kralove, Czech Republic). 2026;69(2):75-80. doi:10.14712/18059694.2026.22

BibTeX
@article{Ehler2026,
  author = {Ehler, Edvard and Jurka, Tomáš and Štětkářová, Ivana},
  title = {Refractory Form of Chronic Idiopathic Demyelinating Polyneuropathy with Rituximab Effect: A Case Report},
  journal = {Acta Medica (Hradec Kralove, Czech Republic)},
  year = {2026},
  volume = {69},
  number = {2},
  pages = {75--80},
  doi = {10.14712/18059694.2026.22}
}
Kostenlos starten →